As Anthem Biosciences’ ₹3,395 crore IPO enters Day 2 of subscriptions, the Bengaluru-based CRDMO player is already fully subscribed. With a unique business model rooted in innovation-led drug ...

Anthem ticks all the boxes. But with lofty valuations and limited margin headroom, analysts warn the IPO may not deliver ...

By Kashish Tandon (Reuters) -Indian drugmaker Anthem Biosciences' [ANTH.NS] $395 million IPO was fully subscribed on the second day of bidding on Tuesday, as investors bet on its growth prospects as ...

The IPO opened for subscription on July 14, aims to raise Rs 3,395 crore through a complete offer for sale (OFS) of 5.96 ...

Anthem Biosciences IPO got fully subscribed at 1.15 times on the second day of share sale on July 15. The initial share sale ...

The mainline issue will close for public subscription on Wednesday, July 16. The basis of allotment of shares is likely to be ...

The grey market premium for Anthem Biosciences IPO rose from Rs 116 on Monday to Rs 123, as of 10:32 a.m., according to ...

Anthem Biosciences IPO sees 20% GMP premium and strong subscriptions on Day 2; check allotment, listing, and key dates now!

Anthem Biosciences raised ₹1,016.02 crore from 60 institutional investors ahead of its IPO launch on July 14. The offering, ...

Anthem Biosciences is selling its shares in the price band of Rs 540-570, applied for a minimum of 26 shares and its multiples to raise a total of Rs 3,395 crore between July 14-16.

Anthem Biosciences has launched its IPO on July 14, closing on July 16. The ₹3,395 crore offer is entirely for sale by ...